IL-6 blockade not only induces immunogenic cell death in tumor cells but also reprograms TAMs toward an anti-tumoral phenotype, effectively reversing resistance to ICIs while minimizing immune-related adverse events [140, 141]. This evidence concerns the gene IL6 and neoplasm.